Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 405-411

  Morita, Sachi ^a   Uehara, Keisuke ^b   Nakayama, Goro ^b   Shibata, Takashi ^a   Oguri, Tomoyo ^b   Inada Inoue, Megumi ^a   Shimokata, Tomoya ^a   Sugishita, Mihoko ^a   Mitsuma, Ayako ^a   Ando, Yuichi ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Hypertension; SNPs; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULOTROPIN GENE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874112483     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2028-2     Document Type: Article

References (18)

1. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
2. Facemire CS, Nixon AB, Grifiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652-658
3. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C et al (2009) Arterial hypertension correlates with clinical outcome in cokorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227-230
4. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596-604
5. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137-2143
7. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cel lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949-954
8. Jain L, Sissung TM, Danesi R, Kohn E, Dahut WL, Kummar S et al (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95
9. Stefano AD, Carlomagno C, Pepe S, Bianco R, Placido SD (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68:1207-1213
10. Mohammadi M, Ollier WE, Hutchinson IV (2003) A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated PBM cells. Hum Immunol 64:S125
11. Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M et al (2010) Dose-finding study and pharmacogenomics analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. B J Cancer 103:1529-1535
12. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Rec 37:443-448
13. Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X et al (2010) Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 71:921-928
14. Ungerback J, Elander N, Dimberg J, Soderkvist P (2009) Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population. Mol Med Report 2:435-439
15. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Nat Cancer Inst 103:763-773
16. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA et al (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554-7563
17. Loupaks F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P et al (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:247
18. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos F-I, Koumarianou A, Varthalitis I et al (2011) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-base chemotherapy and bevacizumab. Pharmacogenomics J. doi: 10.1038/tpj.2011.37